How Joenja works
Joenja is designed to correct the underlying immune defect caused by APDS to help normalize the hyperactive PI3Kδ pathway1-3
Jump to section:
How Joenja works
Joenja in action
HOW JOENJA WORKS
Joenja is the first and only precision therapy that corrects the underlying immune defect in patients with APDS1,2,4
Only Joenja specifically targets and blocks the PI3Kδ protein, addressing immune dysregulation and deficiency at the earliest stage of the PI3K pathway1-3
PI3Kδ signaling in B and T cells
Note: Illustration does not include all steps in the signaling pathway.
Joenja facilitates a balanced PI3Kδ pathway to support proper immune function1-3
JOENJA IN ACTION
Joenja mechanism of action
This video provides a detailed illustration of the mechanism of action for Joenja and shows how only Joenja addresses both immune deficiency AND immune dysregulation to help normalize immune balance.1-4
Clinical Trials
→
APDS Assist
→
AKT/PKB, protein kinase B; APDS, activated PI3Kδ syndrome; FOXO, forkhead box O; mTOR, mammalian target of rapamycin; p85α, the regulatory subunit of the PI3Kδ enzyme; p110δ, the catalytic subunit of the PI3Kδ enzyme; PDK1, phosphoinositide-dependent kinase 1; PIP2, phosphatidylinositol (4,5)-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-trisphosphate.
References: 1. Joenja (leniolisib). Prescribing information. Pharming Healthcare, Inc. 2. Rao VK, Webster S, Šedivá A, et al. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome. Blood. 2023;141(9):971-983. doi:10.1182/blood.2022018546 3. Rao VK, Webster S, Šedivá A, et al. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome. Supplemental. Blood. 2023;141(9):971-983. doi:10.1182/blood.2022018546 4. Pharming Group. Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS. Press release. March 24, 2023. Accessed January 9, 2026. https://www.pharming.com/news/pharming-announces-us-fda-approval-joenja-leniolisib-first-and-only-treatment-indicated-apds
